GlassScriptPhysician profile
Maritza Tovar Day
NPI 1508060088
$2,065.43
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $783 · 2021: $634 · 2022: $261.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $192.74 | 2019-2022 | |
| Lilly USA, LLC | $187.09 | 2019-2022 | |
| Novo Nordisk INC | $186.92 | 2019-2022 | |
| Abbvie INC. | $184.91 | 2021-2022 | |
| Amarin Pharma, INC. | $176.84 | 2019-2021 | |
| Allergan, INC. | $127.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.76 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $58.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.73 | 2020-2022 | |
| Mylan Specialty L.P. | $33.29 | 2020 | |
| Merck Sharp & Dohme LLC | $31.62 | 2019-2020 | |
| Eisai INC. | $30.02 | 2020-2021 | |
| Genentech USA, INC. | $25.66 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.97 | 2021 | |
| Pfizer INC. | $24.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $23.24 | 2021 | |
| Esperion Therapeutics, INC. | $21.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2021 | |
| Astellas Pharma US INC | $15.02 | 2019 | |
| Abbott Laboratories | $13.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.11 | 2019 | |
| Dermira, INC. | $11.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritza Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.